newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple Ascending Dose ("MAD") clinical trial of fezagepras Repa